Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1HIV Infections 1

Interventions

Cytarabine 25Azacitidine 17fludarabine phosphate 15fludarabine 15Cyclophosphamide 14venetoclax 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 8Busulfan 8Granulocyte Colony-Stimulating Factor 7Filgrastim 7Whole-Body Irradiation 6Decitabine 6Cyclosporine 6Injections 5Idarubicin 5decitabine and cedazuridine drug combination 4Tacrolimus 4Radiotherapy 4Mycophenolic Acid 4Mitoxantrone 4Daunorubicin 4Cladribine 4CPX-351 4Biopsy 4midostaurin 3merphos 3magrolimab 3gilteritinib 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myeloid, Acute × Transplantation Conditioning × Clear all
NCT04395092 2021-06-22

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Kiadis Pharma

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡